Over saturation? You’ve just evidenced that you have no clue what you’re talking about. Abbvie has always had many more reps than Biohaven does as well as a much more robust budget, yet we’ve more than held our own. Cutting back on the footprint would only give them room to take over and run away with market share. Biohaven managed to do what we’ve done with a fraction of a sales force that our competition has. Pfizer bought us for one reason: CGRP. Nurtec is the only medication we have so they are going to expect to see a sizable return in that investment and cutting back while the competition outnumbers them isn’t going to do it. They are going to want to overtake Ubrelvy pure and simple.
